China Licensing

Briding the gap for Western life sciences companies to Asia

JOINT VENTURE WITH YAFO CAPITAL, LTD.

With the idea to have representatives for licensing transactions in Europe and in China, FCF Life Sciences formed a joint venture with Yafo Capital, Ltd. in 2019. Together, we form a unique team to address the needs of our European and Asian clients. Our aim is to facilitate and guarantee a smooth partnering process.

Facts on Yafo Capital, Ltd.

  • Shanghai based advisory firm
  • Established network and access to leading 200+ Pharma and MedTech companies in Asia
  • Team of 20+ professionals with banking and healthcare background
  • ~20 completed transactions within the last five years

ACCESS CHINA FORUM

0
Company presentations
0
Participants
0
Meeting requests
0
Assets presented
FCF co-organizes, together with its partner YAFO Capital, the “ACCESS CHINA Forum”, which will be held online 4x per year.

ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable business development opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations.

UPCOMING EVENT

FCF Biotech Venture Capital Monitor – USA 09/2022 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 09/2022”.

The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector.

As of the end of  September 2022, we identify the following current VC trends in the US-Biotech sector:

  • In 2022, overall Biotech funding in the USA has reached USD 23,869m so far
  • The top 5 deals exceed USD 340m each, largest transaction amounted to USD 3,000m in Altos Labs
  • ARCH Venture Partners (USA) is leading the Top 5 Investors (by deal volume), followed by 8VC (USA) and Alexandria Venture Investments (USA)
  • Oncology dominates as the top indication

To access the full report, please click here.

By Dr. Mathias Schott, Sebastian Sommer and Johannes Link

Share

If you are interested in exploring China licensing opportunities, please contact us:

[a-zA-Z0-9_.-]
[a-zA-Z0-9_.-]
[a-zA-Z0-9]
[a-zA-Z0-9]